Loading...

Financial Summary


Insys Therapeutics Inc.

Insys Therapeutics Inc. (INSY)

Healthcare
Buy
A
Market Info
Financial Info
Financial Modelling
Symbol INSY
Price 0.86$
Beta 2.48
Volume Avrg. 0.63M
Market Cap 0.06B
Shares (2018) 74,073.66K
Last Div 0
Dividend Yield -
DCF Unlevered -0.61 Strong Sell
DCF Levered 3.42 Strong Buy
ROE 288.88% Strong Buy
ROA -173.89% Strong Sell
Operating Margin -155.61% Strong Sell
Debt / Equity 0.00% Neutral
P/E - Neutral
P/B - Neutral

Income Statement

Download INSY income statement Download INSY income statement
Year 2011 2012 2013 2014 2015 2016 2017 2018
Earnings Per Share Basic -0.69-0.872.341.100.820.11-3.16-1.68
Net Profit Margin --1.580.410.170.180.03-1.62-1.52
Earnings Per Share Diluted -0.69-0.872.111.040.770.10-3.16-1.68
Revenue -15.4899.29222.13330.80242.28140.6982.08
Weighted Average Shares Outstanding --17.2834.3871.5971.6272.2674.07
Gross Profit -7.8586.62199.55301.94216.88120.0571.28
Weighted Average Shares Outstanding (Diluted) 2.3527.9519.1636.6775.7174.1572.2674.07
Sales, General and Administrative Expense 9.0419.5845.57102.39144.72131.74116.4470.64
Dividend per Share --------
Operating Income -17.37-23.4432.5664.0292.437.33-219.03-127.72
Gross Margin -0.510.870.900.910.900.850.87
Earnings before Tax -19.36-24.3831.5864.1892.978.42-217.19-126.41
EBITDA Margin --1.290.350.300.300.06-1.50-1.46
Net Income -19.36-24.3840.3837.9858.487.59-228.01-124.51
EBIT Margin --1.400.330.290.280.03-1.56-1.56
Net Income - Discounted ops --------
Profit Margin --1.570.410.170.180.03-1.62-1.52
Preferred Dividends -17.73-------
Free Cash Flow margin --0.000.000.000.000.00-0.00-0.00
R&D Expenses 8.336.308.5033.1455.2873.9162.9557.57
Interest Expense 1.962.680.93-----
Earnings Before Tax Margin --1.580.320.290.280.03-1.54-1.54
Consolidated Income -19.36-24.3840.3837.9858.487.59-228.01-124.51
EBIT -17.40-21.6932.5664.0292.437.33-219.03-127.72
EBITDA -16.01-20.0334.3566.5297.7215.60-210.57-120.12
Income Tax Expense ---8.8026.2034.490.8310.82-1.90
Operating Expenses 17.3731.2954.06135.52209.51209.56339.08199.00
Cost of Revenue -7.6312.6622.5828.8525.3920.6410.80
Net Income Com -1.63-24.3840.3837.9858.487.59-228.01-124.51
Net Income - Non-Controlling int --------

Balance Sheet Statement

Download INSY income statement Download INSY income statement
Year 2011 2012 2013 2014 2015 2016 2017 2018
Total current liabilities 61.7083.4216.8845.6888.8678.61207.18106.86
Other Liabilities 0.986.70-4.04----125.00
Long-term debt --------
Cash and cash equivalents 0.010.3645.3858.1179.52104.6432.0031.55
Total debt 52.8170.24------
Cash and short-term investments 0.010.3645.3882.86159.09237.97168.4295.68
Deferred revenue -3.77----1.111.86
Inventories 6.747.0914.5334.7841.7221.7417.418.61
Tax Liabilities --0.335.379.019.8010.135.06
Goodwill and Intangible Assets 5.40-------
Deposit Liabilities --------
Tax assets --3.804.6116.3323.245.635.40
Total non-current liabilities 2.47-8.243.788.637.938.623.77
Total current assets 13.056.8582.15151.04253.24230.97175.94126.29
Total liabilities 64.1783.4221.0849.4597.4986.55215.80235.63
Payables 7.906.4816.5627.4536.3527.3630.4450.86
Other comprehensive income --168.50216.39245.72256.51278.33292.51
Short-term investments ---24.7679.58133.33136.4264.13
Retained earnings (deficit) -105.03-129.41-89.03-51.067.4212.66-215.35-336.08
Property, Plant & Equipment Net 7.486.7910.1329.8738.3843.1755.1752.09
Total non-current assets 2.47-18.4164.0897.96125.16103.1466.23
Other Assets 1.161.34------
Net Debt 52.8069.88-45.38-58.11-79.52-104.64-32.00-31.55
Investments ---48.02122.80133.33136.4272.57
Total shareholders equity -43.21-64.6879.48165.67253.70269.5963.28-43.10
Total assets 20.9618.74100.56215.12351.20356.14279.08192.53
Long-term investments ---23.2643.22--8.45
Receivables -3.0916.3126.5448.4620.6521.5112.61
Short-term debt 52.8170.24------

Cash Flow Statement

Download INSY income statement Download INSY income statement
Year 2011 2012 2013 2014 2015 2016 2017 2018
Insurance (repayment) of debt --------
Net Cash/Marketcap 0.000.00------
Insurance (buybacks) of shares --------
Depreciation & Amortization 1.391.661.792.505.298.288.467.61
Dividend payments --------
Operating Cash Flow -15.38-13.6324.2549.66100.8558.90-60.66-55.99
Acquisitions and disposals --------
Free Cash Flow -15.98-14.6519.1227.4287.0148.29-77.32-62.08
Net cash flow / Change in cash -0.050.3545.0212.7221.4125.13-72.64-0.45
Effect of forex changes on cash --------
Financing Cash Flow 15.9315.0026.3032.959.30-11.745.832.14
Investment purchases and sales ----48.04-91.3679.9198.45121.22
Capital Expenditure -0.60-1.025.1322.2513.8410.6116.666.09
Stock-based compensation 1.692.766.3415.2920.3821.5916.0212.02
Investing Cash Flow --------

Retained Earning Schedule

Year 2011 2012 2013 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) --105-129-89-51713-215
Net Income -19-244038588-228-125
Stock Dividends -86-----2-4
Divident Paid --------
Retained Earnings -105-129-89-51713-215-336

PPE Schedule

Year 2011 2012 2013 2014 2015 2016 2017 2018
Year 20112012201320142015201620172018
Gross PPE -771030384355
Annual Depreciation 80-2-3-5-6-5-9
Capital Expenditure -1-15221411176
Net PPE 77103038435552

Intangible and Goodwill Schedule

Year 2011 2012 2013 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -5------
New Purchases ----48-918098121
Intangible and Goodwill 5-------
Insys Therapeutics Inc.

Insys Therapeutics Inc. (INSY)

0.86
0 (-0.28%)

About


Healthcare
Biotechnology
NASDAQ Global Market

Insys Therapeutics Inc develops and commercializes drugs delivery systems targeting the oncology space. The company manufactures cannabinoid formulation, and sublingual spray drug delivery technology for the US and Europe markets.